Swiss biotechnology company Araris Biotech AG, a member of grow cluster, has announced a research collaboration and license agreement with Japanese pharmaceutical company Chugai Pharmaceutical Co. Araris specializes in the development of antibody-drug conjugates (ADCs). This technology allows for the attachment of multiple therapeutic payloads to antibodies in a single step. With this approach, Araris aims to enable cancer treatments without the need for chemotherapy.
The goal of the collaboration with Chugai is to develop next-generation ADCs using Araris’ patented AraLinQ™ technology. Under the terms of the agreement, Chugai will fund the research activities and provide specific antibodies. After exercising the license option, Chugai will take responsibility for further development, manufacturing, and global commercialization of the ADCs. Araris will receive milestone payments of up to USD 780 million as well as royalties on product sales.
“This second partnership with a leading pharmaceutical company highlights the potential of our platform,” said Dr. Philipp Spycher, Chief Scientific Officer and co-founder of Araris. In 2023, Araris had already entered a research partnership with Taiho Pharmaceutical Co., Ltd., a Japanese company specializing in oncology.
More information: www.ararisbiotech.com